Published in Nat Genet on April 15, 2007
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 9.42
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25
The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest (2012) 3.09
Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A (2009) 2.99
PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 2.66
Segmental duplications arise from Pol32-dependent repair of broken forks through two alternative replication-based mechanisms. PLoS Genet (2008) 2.54
The c-myb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells. Blood (2008) 2.34
The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood (2008) 1.95
WT1 mutations in T-ALL. Blood (2009) 1.75
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 1.68
MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol (2011) 1.61
Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev (2010) 1.54
c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J Clin Invest (2010) 1.52
Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell (2012) 1.43
Alu elements mediate MYB gene tandem duplication in human T-ALL. J Exp Med (2007) 1.37
microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic Acids Res (2010) 1.32
Fragile genomic sites are associated with origins of replication. Genome Biol Evol (2009) 1.32
Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. PLoS Genet (2013) 1.29
Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood (2015) 1.19
New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer. Cell Cycle (2010) 1.16
Integrated genome-wide chromatin occupancy and expression analyses identify key myeloid pro-differentiation transcription factors repressed by Myb. Nucleic Acids Res (2011) 1.13
Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia. Blood (2013) 1.13
c-Myb promotes the survival of CD4+CD8+ double-positive thymocytes through upregulation of Bcl-xL. J Immunol (2010) 1.05
Alternative RNA splicing produces multiple forms of c-Myb with unique transcriptional activities. Mol Cell Biol (2008) 1.04
Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis. Blood (2008) 1.04
Fbxw7 acts as an E3 ubiquitin ligase that targets c-Myb for nemo-like kinase (NLK)-induced degradation. J Biol Chem (2008) 1.03
Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency. Leukemia (2012) 1.03
Global genomic characterization of acute lymphoblastic leukemia. Semin Hematol (2009) 1.02
MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia. Leukemia (2014) 1.02
Zebrafish microRNA-126 determines hematopoietic cell fate through c-Myb. Leukemia (2010) 1.00
Reduced c-Myb activity compromises HSCs and leads to a myeloproliferation with a novel stem cell basis. EMBO J (2009) 1.00
The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer (2016) 1.00
c-Myb regulates matrix metalloproteinases 1/9, and cathepsin D: implications for matrix-dependent breast cancer cell invasion and metastasis. Mol Cancer (2012) 0.98
Combined interphase fluorescence in situ hybridization elucidates the genetic heterogeneity of T-cell acute lymphoblastic leukemia in adults. Haematologica (2010) 0.98
MicroRNAs as regulatory elements in immune system logic. Nat Rev Immunol (2016) 0.97
Myb proteins: angels and demons in normal and transformed cells. Front Biosci (Landmark Ed) (2011) 0.96
MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. Acta Neuropathol (2010) 0.96
Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia. Blood (2010) 0.95
The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy. Ther Adv Hematol (2013) 0.94
Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol (2016) 0.94
Cross-species array comparative genomic hybridization identifies novel oncogenic events in zebrafish and human embryonal rhabdomyosarcoma. PLoS Genet (2013) 0.94
Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells. Endocrinology (2008) 0.94
Activation of miR200 by c-Myb depends on ZEB1 expression and miR200 promoter methylation. Cell Cycle (2013) 0.93
Frequent activation of EGFR in advanced chordomas. Clin Sarcoma Res (2011) 0.92
PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia. Blood (2015) 0.91
c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells. Leukemia (2011) 0.89
Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments. Curr Hematol Malig Rep (2012) 0.89
Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation. Haematologica (2015) 0.89
Three murine leukemia virus integration regions within 100 kilobases upstream of c-myb are proximal to the 5' regulatory region of the gene through DNA looping. J Virol (2012) 0.88
Role of TLX1 in T-cell acute lymphoblastic leukaemia pathogenesis. Br J Haematol (2009) 0.88
PIAS1 interacts with FLASH and enhances its co-activation of c-Myb. Mol Cancer (2011) 0.88
c-myc copy number gain is a powerful prognosticator of disease outcome in cervical dysplasia. Oncotarget (2015) 0.87
Pediatric low-grade gliomas: how modern biology reshapes the clinical field. Biochim Biophys Acta (2014) 0.86
Situational awareness: regulation of the myb transcription factor in differentiation, the cell cycle and oncogenesis. Cancers (Basel) (2014) 0.85
Single-cell transcriptional analysis of normal, aberrant, and malignant hematopoiesis in zebrafish. J Exp Med (2016) 0.85
Deciphering causal and statistical relations of molecular aberrations and gene expressions in NCI-60 cell lines. BMC Syst Biol (2011) 0.84
Transient responses to NOTCH and TLX1/HOX11 inhibition in T-cell acute lymphoblastic leukemia/lymphoma. PLoS One (2011) 0.83
Distinct regulation of c-myb gene expression by HoxA9, Meis1 and Pbx proteins in normal hematopoietic progenitors and transformed myeloid cells. Blood Cancer J (2012) 0.83
Characterization of a set of tumor suppressor microRNAs in T cell acute lymphoblastic leukemia. Sci Signal (2014) 0.82
Single molecule analysis of c-myb alternative splicing reveals novel classifiers for precursor B-ALL. PLoS One (2011) 0.81
An integrated analysis of molecular aberrations in NCI-60 cell lines. BMC Bioinformatics (2010) 0.81
Impaired adult myeloid progenitor CMP and GMP cell function in conditional c-myb-knockout mice. Cell Cycle (2012) 0.81
Transcriptional network control of normal and leukaemic haematopoiesis. Exp Cell Res (2014) 0.78
An isoform-specific C/EBPβ inhibitor targets acute myeloid leukemia cells. Leukemia (2016) 0.77
Gene expression profiling of murine T-cell lymphoblastic lymphoma identifies deregulation of S-phase initiating genes. Leuk Res (2013) 0.76
Role of c-Myb in the survival of pre B-cell acute lymphoblastic leukemia and leukemogenesis. Am J Hematol (2012) 0.76
Stress-induced phosphorylation of Thr486 in c-Myb by p38 mitogen-activated protein kinases attenuates conjugation of SUMO-2/3. J Biol Chem (2013) 0.76
IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias. PLoS One (2016) 0.76
c-myb hyperactivity leads to myeloid and lymphoid malignancies in zebrafish. Leukemia (2016) 0.75
MYB deregulation from a EWSR1-MYB fusion at leukemic evolution of a JAK2 (V617F) positive primary myelofibrosis. Mol Cytogenet (2016) 0.75
Distal regulation of c-myb expression during IL-6-induced differentiation in murine myeloid progenitor M1 cells. Cell Death Dis (2016) 0.75
New flow cytometry in hematologic malignancies. Haematologica (2009) 0.75
Morphologically low-grade spiradenocarcinoma: a clinicopathologic study of 19 cases with emphasis on outcome and MYB expression. Mod Pathol (2015) 0.75
Stem Cell Leukemia: how a TALented actor can go awry on the hematopoietic stage. Leukemia (2016) 0.75
The chicken miR-150 targets the avian orthologue of the functional zebrafish MYB 3'UTR target site. BMC Mol Biol (2010) 0.75
NF-κB in T-cell Acute Lymphoblastic Leukemia: Oncogenic Functions in Leukemic and in Microenvironmental Cells. Cancers (Basel) (2010) 0.75
miR-150 Regulates Memory CD8 T Cell Differentiation via c-Myb. Cell Rep (2017) 0.75
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol (2002) 82.19
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol (2007) 16.15
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79
Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med (2004) 11.61
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. N Engl J Med (2008) 10.88
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet (2009) 8.03
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
Gene prioritization through genomic data fusion. Nat Biotechnol (2006) 7.48
Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 7.38
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 6.67
Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology (2006) 6.55
A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol (2009) 6.25
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet (2010) 4.90
High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med (2009) 4.90
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59
Elimination of primer-dimer artifacts and genomic coamplification using a two-step SYBR green I real-time RT-PCR. Anal Biochem (2002) 4.54
Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet (2003) 4.44
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
Cytarabine dose for acute myeloid leukemia. N Engl J Med (2011) 4.15
Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nat Genet (2004) 4.09
The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol (2004) 3.94
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 3.93
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology (2005) 3.90
Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am J Hum Genet (2005) 3.87
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol (2008) 3.47
T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol (2008) 3.45
The structure-specific endonuclease Mus81 contributes to replication restart by generating double-strand DNA breaks. Nat Struct Mol Biol (2007) 3.38
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol (2009) 3.07
Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica (2008) 3.06
RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res (2003) 3.06
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet (2004) 2.96
Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell (2011) 2.89
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med (2012) 2.86
High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood (2008) 2.86
In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell (2008) 2.78
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol (2012) 2.78
High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. Nucleic Acids Res (2008) 2.71
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell (2003) 2.70
PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 2.66
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet (2012) 2.64
Rapid detection of VHL exon deletions using real-time quantitative PCR. Lab Invest (2005) 2.61
CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood (2011) 2.59
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood (2009) 2.57
Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet (2007) 2.55
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol (2008) 2.51
Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med (2008) 2.49
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood (2010) 2.42
The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. Mol Cell (2010) 2.38
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood (2013) 2.34
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet (2011) 2.32
A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell (2011) 2.29
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol (2012) 2.29
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res (2008) 2.27
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res (2006) 2.23
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol (2013) 2.22
Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol (2009) 2.21
Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood (2009) 2.19
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood (2005) 2.14
Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood (2003) 2.13
Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma (2008) 2.12
RTPrimerDB: the real-time PCR primer and probe database, major update 2006. Nucleic Acids Res (2006) 2.11
Conservation of hotspots for recombination in low-copy repeats associated with the NF1 microdeletion. Nat Genet (2006) 2.11
Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst (2009) 2.09
Medical end-of-life decisions for children in the Netherlands. Arch Pediatr Adolesc Med (2005) 2.09
No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy. Pediatr Blood Cancer (2012) 2.08
Molecular karyotyping: array CGH quality criteria for constitutional genetic diagnosis. J Histochem Cytochem (2005) 2.05